Topline results of PALISADE-3 Phase 3 Trial of fasedienol for acute treatment of social anxiety disorder expected in the fourth quarter of 2025 PALISADE-4 Phase 3 Trial topline results expected in the first half of 2026 Vistagen continues to advance diverse intranasal pherine pipeline targeting treatments in psychiatry, women’s health, and cancer supportive care SOUTH SAN FRANCISCO, Calif. / Aug 07, 2025 / Business Wire /... Read More